Finisar Corp. (FNSR) Financials Nov 14, 2014, 4:56
Finisar Corp. (FNSR) Financials Nov 14, 2014, 4:56 p.m.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for Finisar Corp.
Fiscal year is May-April. All values USD millions. 2010 2011 2012 2013 2014 5-year trend
Sales/Revenue 629.88M 948.79M 952.58M 934.34M 1.16B
Cost of Goods Sold (COGS) incl. D&A 452.17M 638.05M 682.73M 684.29M 762.3M
COGS excluding D&A 414.84M 588.32M 626.52M 609.29M 692.15M
Depreciation & Amortization Expense 37.33M 49.73M 56.21M 75M 70.15M
Depreciation 30.53M 43.51M 45.56M 52.8M 62.01M
Amortization of Intangibles 6.8M 6.22M 10.65M 22.2M 8.14M
Gross Income 177.71M 310.74M 269.85M 250.04M 394.53M
2010 2011 2012 2013 2014 5-year trend
SG&A Expense 162.24M 199.03M 235.45M 240.55M 263.31M
Research & Development 94.77M 117.28M 146M 158.78M 183.36M
Other SG&A 67.47M 81.74M 89.44M 81.77M 79.96M
Other Operating Expense 0 0 0 0 0
Unusual Expense 31.1M 8.34M (14.8M) 15.04M 19.81M
EBIT after Unusual Expense (31.1M) (8.34M) 14.8M (15.04M) (19.81M)
Non Operating Income/Expense 0 (4.72M) (1.55M) (449,000) 6.65M
Non-Operating Interest Income 144,000 530,000 1.07M 755,000 1.32M
Equity in Affiliates (Pretax) 0 0 0 - -
Interest Expense 8.96M 6.37M 3.72M 2.59M 5.55M
Gross Interest Expense 8.96M 6.37M 3.72M 2.59M 5.55M
Interest Capitalized 0 0 0 0 0
Pretax Income (24.45M) 92.83M 45.02M (7.84M) 113.84M
Income Tax (1.64M) 4.45M 2.01M 227,000 2.88M
Income Tax - Current Domestic - - 199,000 (45,000) 138,000
Income Tax - Current Foreign - - 3.61M 3.9M 5.69M
Income Tax - Deferred Domestic - - 0 (3.62M) 0
Income Tax - Deferred Foreign - - (1.8M) - (2.95M)
Income Tax Credits - - 0 - -
Equity in Affiliates 0 0 0 0 -
Other After Tax Income (Expense) 0 0 0 0 0
Consolidated Net Income (22.81M) 88.38M 43.01M (8.07M) 110.95M
Minority Interest Expense 0 0 21,000 (2.61M) (835,000)
Net Income (22.81M) 88.38M 42.99M (5.45M) 111.79M
Extraordinaries & Discontinued Operations 36.94M (284,000) 0 0 0
Extra Items & Gain/Loss Sale Of Assets 0 0 0 0 0
Cumulative Effect - Accounting Chg 0 0 0 0 0
Discontinued Operations 36.94M (284,000) 0 0 0
Net Income After Extraordinaries 14.13M 88.1M 42.99M (5.45M) 111.79M
Preferred Dividends 0 0 0 0 0
Net Income Available to Common (22.81M) 88.38M 42.99M (5.45M) 111.79M
EPS (Basic) 0.22 1.09 0.47 (0.06) 1.16
Basic Shares Outstanding 64.95M 80.58M 90.82M 92.86M 95.98M
EPS (Diluted) 0.22 0.95 0.46 (0.06) 1.09
Diluted Shares Outstanding 64.95M 92.72M 94.19M 92.86M 104.11M
EBITDA 52.8M 161.44M 90.62M 84.49M 201.37M
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Education Meets Innovation: Savvas Takes a Bold Step Who would have thought biology education could get a makeover that might actually stick? Savvas Learning Company thinks it's onto something with the launch of the all-new Miller & Levine Experience Biology Program. The spotlight's on innovation—it's about time someone shook up the way high schoolers learn biology. A...
Continue Reading
Housing is one of those things we all think we understand until we start peeling back the layers of its history, especially when factory-built homes are involved. Here's a new angle: Clayton has just released the teaser for their documentary short, "Built: A Story of Factory-Built Housing in America," and it's turning the lights on a sector that's often left in the...
Continue Reading
Turning Talk into Triumphs Award chatter isn't exactly rare in this industry, but the latest accolades rolling in for transcosmos from the Best Contact Center Indonesia 2026 ain't your run-of-the-mill pat on the back. Sure, a trophy's a trophy, but when they snatch Gold in the Business Contribution category and another shiny Silver in People Development, it’s hinting at...
Continue Reading
The Unicycive Landslide: What Went Down? Investors, buckle up. Unicycive Therapeutics Inc. (NASDAQ: UNCY) finds itself deep in the muck of a securities class action. Chief honchos, CEO Shalabh Gupta and CFO John Townsend, are taking the heat for allegedly controlling company disclosures that led shareholders to believe in non-existent progress with their third-party...
Continue Reading
SoftwareOne Nabs Prestigious GitHub Honor Outta nowhere, SoftwareOne's been lashed onto the center stage, bagging GitHub's Global Channel Sales Partner of the Year for 2026. This ain't just another shiny trophy on the shelf; it's a solid nod to their grit and strategy. Now, if good old GitHub says you're their top dog, you're obviously doing something right. Not bad for a...
Continue Reading
Data Centers: The Unseen Powerhouses Don't let the tech jargon fool you—data centers are more than just server rooms. They're beastly energy guzzlers, and their demand is rippling through the supply chain in a big way. You've got companies like Vertiv, American Tower, Johnson Controls, and Generac riding high on this trend, making some serious waves in their quarterly...
Continue Reading
Another Day, Another Data Breach It seems like you can’t throw a stone without hitting a data breach these days—and this time, it’s Lumara Bio USA’s turn under the spotlight. The Princeton-based oncology therapeutics outfit, part of Germany’s ITM Isotope Technologies, spilled some beans it never meant to. We're talking some pretty sensitive stuff here, folks....
Continue Reading
The Challenge of Moving AI to Production Diving headfirst into AI in finance? Well, Jacobi's bold move with their new toy, the Investment Management Harness, spotlights a filthy secret: the hurdles between a big idea and execution are seldom technological. We got AI shaving prototyping time down to just days, yet pushing to production? That's a marathon in itself. Boards...
Continue Reading
A New Chapter for Women in Aviation Call it paving the skies or busting the glass cockpit ceiling, but Air Canada and CAE are really doubling down on getting more women into aviation. They're rolling out the eighth annual Captain Judy Cameron Scholarship, set to open applications on November 1, 2026. With up to eight scholarships on the table for Canadian women eyeing...
Continue Reading
Hope Charities Takes a Stand for Patients In Prairieville, Hope Charities is throwing its weight behind a bill they believe is brewing up a patient revolution. The Patients Choice in Specialty Pharmacy Act, otherwise known as H.R. 10549, sparked by Representatives Neal Dunn and Joe Wilson, tackles the comfortable partnerships some insurers have been enjoying with their...
Continue Reading
Top 5 Most Recently Viewed Articles
ClickBid Introduces Groundbreaking AI Assistant ClickBid, recognized as a pioneer in event fundraising technology, proudly presents ClickBid Search. This is the first custom GPT-powered AI assistant tailored specifically for nonprofits, designed to offer immediate and relevant answers to help organizations optimize their event strategies. Available at no cost to all...
Continue Reading
Autonomous Driving Gets a German Boost Well folks, looks like the autonomous vehicle scene is hitting the autobahns with more horsepower than ever before. Today’s chatter is all about how TIER IV and the Technical University of Munich (TUM) have teamed up, tapping into the grid as they ride the waves of cutting-edge NVIDIA tech. The Sparks Under the Hood: NVIDIA...
Continue Reading
Vericel Corporation's Engagement at the MedTech Conference CAMBRIDGE, Mass. — Vericel Corporation (NASDAQ:VCEL), a recognized leader in advanced therapies for sports medicine and severe burn care, has exciting news regarding its participation at the upcoming Truist Securities MedTech Conference. The company will be featured in a fireside chat, slated to take place at...
Continue Reading
Gildan Reports Remarkable Growth in Second Quarter Earnings Gildan Activewear Inc. (NYSE: GIL, TSX: GIL) has achieved record net sales of $919 million during the second quarter, reflecting a strong 6.5% increase compared to the previous year. Strong Operational Performance and Profitability This quarter's operating margin stood at an impressive 21.7%, with an adjusted...
Continue Reading
MimiVax and UI Pharmaceuticals Mark Key Production Milestone MimiVax and UI Pharmaceuticals have achieved an exciting development in the field of cancer treatment with the clinical manufacture of SurVaxM, an innovative immunotherapeutic vaccine aimed at targeting glioblastoma. SurVaxM proudly stands out as the first product to be manufactured at UI Pharmaceuticals' newly...
Continue Reading